Sonoma Pharmaceuticals Enters Sales Agreement with Ladenburg
I'm PortAI, I can summarize articles.
Sonoma Pharmaceuticals (SNOA) has entered into an At Market Issuance Sales Agreement with Ladenburg Thalmann & Co. Inc. to sell shares of its common stock, allowing for various sale methods. The agreement, effective September 26, 2025, is for an aggregate offering price of up to $2,070,463 under a SEC registration statement. Analysts rate SNOA stock as Hold with a $4.00 price target, citing strong revenue growth but challenges in profitability and cash flow. Technical analysis shows weak momentum, suggesting caution for investors.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Tip Ranks The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments